Alertas Bibliográficas
DIABETES
Effect of dulaglutide on liver fat in patients with type 2 diabetesand NAFLD: randomised controlled trial (D-LIFT trial)
Kuchay M, Krishan S, Mishra S, Choudhary N, Singh M, Wasir J et al
Diabetologia 2020: 63(12)2434–2445
https://doi.org/10.1007/s00125-020-05265-7
Intestinal microbial metabolites in human metabolism and type 2 diabetes
Herrema H and Niess JH
Diabetologia 2020: 63(12):2533 – 2547
https://doi.org/10.1007/s00125-020-05268-4
ENDOCRINOLOGÍA
Adrenal Incidentaloma
Mark Sherlock, Andrew Scarsbrook, Afroze Abbas, Sheila Fraser, Padiporn Limumpornpetch, Rosemary Dineen, Paul M Stewart
Endocrine Reviews, Volume 41, Issue 6, 1 December 2020, bnaa008
https://doi.org/10.1210/endrev/bnaa008
Published: 08 April 2020
Dopamine agonists in prolactinomas: when to withdraw?
Pedro Souteiro, Sandra Belo, Davide Carvalho
https://doi.org/10.1007/s11102-019-00989-1
PEDIATRÍA
Liraglutide in Children and Adolescents with Type 2 Diabetes.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, et al.
N Engl J Med. 2019 Aug 15;381(7):637-646.
http://doi.org/10.1056/NEJMoa1903822
Could AGE/RAGE-Related Oxidative Homeostasis Dysregulation Enhance Susceptibility to Pathogenesis of Cardio-Metabolic Complications in Childhood Obesity?
Corica D, Aversa T, Ruggeri RM, Cristani M, Alibrandi A, et al.
Front Endocrinol (Lausanne). 2019 Jun 28;10:426.
http://doi.org/10.3389/fendo.2019.00426
CIENCIAS BÁSICAS
Mechanisms of Insulin Action and Insulin Resistance.
Petersen MC, Shulman GI.
Physiol Rev. 2018 Oct 1;98(4):2133-2223.
http://doi.org/10.1152/physrev.00063.2017
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Buzzetti E, Pinzani M, Tsochatzis EA.
Metabolism. 2016 Aug;65(8):1038-48.
http://doi.org/10.1016/j.metabol.2015.12.012